英菲格拉替尼是什么药？

The US Food and Drug Administration accelerated its approval for marketing in May 2021. The drug is a kinase inhibitor that induces tumor cell death by reducing cancer cell proliferation. Today let’s take a closer look at what Infigratinib is?

Infigratinib is not currently on the market in China. The drug is indicated for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, accompanied by fibroblast growth factor receptor 2 (FGFR2) fusion or other FDA-approved rearrangements. The drug is also very convenient to take. There is a 28-day cycle, 125 mg is taken orally every day for 21 consecutive days, and then the drug is stopped for 7 days. The patient can continue to take the drug until the disease progresses or intolerable toxicity occurs.

Alterations of FGFR in tumors can lead to constitutive FGFR signaling that supports the proliferation and survival of malignant cells. Infigratinib blocks downstream signaling cascades by selectively binding to and inhibiting FGFR activity. The drug is a small molecule ATP competitive tyrosine kinase inhibitor of FGFR.

The trial studied the efficacy of infigratinib as a third-line or above treatment for patients with FGFR2 fusion-positive cholangiocarcinoma. The results showed that the median PFS of patients who received third-line or above treatment with infigratinib was 6.77 months; in the case of second-line treatment, the median PFS of patients was 4.63 months. In other words, compared with the second-line standard chemotherapy regimen, infigratinib in third-line and above-line treatment has greater benefits in both PFS and ORR. Cholangiocarcinoma is a serious and very fatal disease. The launch of infigratinib brings great hope to patients with cholangiocarcinoma.

The most common adverse reactions of infigratinib (incidence ≥20%): abdominal pain, dry mouth, nail toxicity, stomatitis, dry eye, fatigue, alopecia, dysgeusia, constipation, eyelash changes, diarrhea, dry skin, loss of appetite, palmoplantar erythema sensory syndrome, joint pain, blurred vision and vomiting.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: